Procedures
Implant Types
Shape & Profile
Surface & Brand
Placement
Safety
Patient Info
Blog Free Consultation
Implant Surface · 4 of 4

Polyurethane-coated implants

Foam-coated implants with strong tissue adherence — essentially zero rotation, very low capsular contracture rates. Specialty option for anatomical implants and complex revision. European market dominant; not FDA-approved in USA.

Clinical summary

Polyurethane-coated implants have a foam coating over the silicone shell that encourages strong tissue ingrowth — essentially zero rotation, very low capsular contracture rates. Different mechanism from macrotextured (separate foam layer vs textured silicone surface) and lower BIA-ALCL risk. Manufactured by Polytech (dominant European brand). Best fit: anatomical implants where rotation must be minimised, revision after capsular contracture, complex revision needing strong fixation. Not FDA-approved in USA; available in EU and other markets.

The four surface categories

SurfaceTexture scaleBIA-ALCL risk profileBest for
SmoothPolished/glossyEssentially undetectableRound implants where rotation doesn't matter
MicrotexturedFine surface roughness (~50-100 µm)Lower than macrotexturedAnatomical implants; modern standard
MacrotexturedCoarser pores (~200-700 µm)Higher (BIOCELL-pattern recalled 2019)Largely withdrawn from market
Polyurethane-coatedFoam-like coatingVery lowSpecialty — strong tissue adherence, low rotation

The surface decision is one of the most clinically meaningful in implant selection. Surface affects rotation risk (anatomical implants need texture; round don't), capsular contracture rates (debated but historically textured had lower rates), and BIA-ALCL risk (specifically associated with macrotextured surfaces).

The polyurethane mechanism

A polyurethane-coated breast implant has three layers:

  1. Inner core — silicone gel filler (cohesive gel of various levels).
  2. Silicone shell — the standard silicone elastomer envelope.
  3. Polyurethane foam coating — approximately 1-2 mm thick foam layer covering the entire shell exterior.

The foam layer is the differentiating feature. When implanted, surrounding tissue grows into the foam over weeks-to-months, creating very firm adhesion. Over years, the polyurethane gradually dissolves and is absorbed by the body — leaving the silicone shell with surrounding tissue firmly adherent to its surface.

The capsular contracture advantage

Polyurethane-coated implants have very low capsular contracture rates in published data:

Surface10-year capsular contracture rate
Smooth (modern)~3-6%
Microtextured~2-5%
Macrotextured (when used)~1-3%
Polyurethane-coated~1-2%

The mechanism: the strong tissue ingrowth into the foam creates a more regular, less contractile capsule. The capsule that forms around polyurethane-coated implants tends to be thinner and less prone to contracture than capsules around other surface types.

The rotation immunity advantage

For anatomical implants, polyurethane-coated essentially eliminates rotation:

Anatomical implant surfaceRotation rate
Smooth anatomical~10-15% (rarely used)
Microtextured anatomical~1-3%
Macrotextured anatomical (when used)~0.5-2%
Polyurethane-coated anatomicalEssentially 0%

For patients with anatomical implant indications (most commonly breast reconstruction) where rotation must be absolutely minimised, polyurethane-coated is among the most established choices in current European practice.

Where polyurethane fits

Brand availability

Polytech is the dominant manufacturer of polyurethane-coated breast implants globally:

BrandPolyurethane productAvailability
PolytechMultiple polyurethane-coated lines (Diagon\Gel 4Two, etc.)EU, UK, many international markets
SilimedPolyurethane-coated variantsBrazil, Latin America, some EU

Polyurethane-coated implants are NOT FDA-approved in the USA — patients seeking polyurethane in the USA must look to international options or wait for potential FDA approval. In Europe and many international markets, polyurethane-coated is widely available alongside other surface options.

Specialty positioning. Polyurethane-coated implants are appropriately positioned as a specialty choice for specific indications — anatomical-rotation-critical cases, capsular contracture revision, complex reconstruction. For most primary augmentation patients, smooth or microtextured will be the appropriate first choice. Polyurethane is the right answer for specific clinical scenarios where its unique properties matter.

Frequently asked questions

What is a polyurethane-coated breast implant?
A polyurethane-coated implant is a silicone shell covered with a thin layer of polyurethane foam. The foam encourages strong tissue ingrowth — far more than microtextured or macrotextured surfaces — creating very firm tissue adherence to the implant. The polyurethane layer is approximately 1-2 mm thick. The result is essentially zero rotation in anatomical shapes and very low capsular contracture rates. Polytech is the dominant manufacturer, particularly in European markets.
Are polyurethane-coated implants still available?
Yes — Polytech polyurethane-coated implants remain widely available in European markets and other regions. They were never subject to the BIOCELL recall (different texture mechanism) and continue to be a specialty option for specific indications. Polyurethane-coated implants are not FDA-approved in the USA — restricted to European, some Asian, and other markets. Patients in the USA seeking polyurethane-coated typically must travel internationally.
How is polyurethane different from macrotextured?
Different mechanism for similar goals. Macrotextured surfaces had coarse pores in the silicone shell itself — rough silicone surface. Polyurethane-coated surfaces have a separate foam layer over the silicone. Both encourage tissue adherence, but through different mechanisms. The polyurethane foam dissolves over years (the foam layer is gradually absorbed), leaving the underlying silicone shell with firmly adherent surrounding tissue. Polyurethane-coated did not have the elevated BIA-ALCL risk seen with BIOCELL macrotextured.
What is the BIA-ALCL risk with polyurethane?
Very low — comparable to or lower than microtextured. Current evidence suggests polyurethane-coated implants have low BIA-ALCL incidence; some long-term European data shows essentially undetectable levels. The polyurethane foam coating apparently does not trigger the same chronic immune stimulation as macrotextured silicone surfaces. Polyurethane is not a higher-risk substitute for macrotextured — it's a different mechanism with different (lower) risk profile.
Who is a candidate for polyurethane-coated implants?
Three patient profiles. (1) Anatomical implants where rotation must be minimised — polyurethane provides essentially zero rotation. (2) Revision after capsular contracture — strong tissue adherence reduces recurrence risk. (3) Complex revision where standard microtextured may not provide adequate fixation. For routine primary augmentation, polyurethane is rarely the first choice — overkill for the indication and limited brand availability vs Mentor/Allergan/Motiva.
How does the cost compare?
Polyurethane-coated implants are generally similar in cost to premium microtextured implants — slightly higher than standard textured. The European market dominance of Polytech polyurethane-coated keeps prices competitive within Europe. For Turkey medical tourism, polyurethane-coated availability and pricing depend on the specific practice's brand relationships; many practices can source Polytech for patients specifically requesting it.

Related references

Photographic assessment by Dr. Erdal

Send 5-angle photographs via WhatsApp. Personal assessment with profile and size recommendation within 24 hours.

WhatsApp +90 544 850 72 32 →